nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—Indomethacin—CXCL8—ovarian cancer	0.00967	0.359	CrCbGaD
Agomelatine—Melatonin—CYP1B1—ovarian cancer	0.00887	0.329	CrCbGaD
Agomelatine—Melatonin—ESR1—ovarian cancer	0.00599	0.223	CrCbGaD
Agomelatine—Infestation—Vinorelbine—ovarian cancer	0.00565	0.00626	CcSEcCtD
Agomelatine—Tremor—Chlorambucil—ovarian cancer	0.00544	0.00602	CcSEcCtD
Agomelatine—Hepatobiliary disease—Vinorelbine—ovarian cancer	0.00535	0.00592	CcSEcCtD
Agomelatine—Agitation—Chlorambucil—ovarian cancer	0.00533	0.00591	CcSEcCtD
Agomelatine—Angioedema—Chlorambucil—ovarian cancer	0.0053	0.00587	CcSEcCtD
Agomelatine—Rash erythematous—Epirubicin—ovarian cancer	0.00508	0.00562	CcSEcCtD
Agomelatine—Back pain—Topotecan—ovarian cancer	0.005	0.00554	CcSEcCtD
Agomelatine—Connective tissue disorder—Vinorelbine—ovarian cancer	0.00499	0.00553	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Docetaxel—ovarian cancer	0.00481	0.00533	CcSEcCtD
Agomelatine—Angioedema—Topotecan—ovarian cancer	0.00472	0.00523	CcSEcCtD
Agomelatine—Infection—Chlorambucil—ovarian cancer	0.0047	0.00521	CcSEcCtD
Agomelatine—Rash erythematous—Doxorubicin—ovarian cancer	0.0047	0.0052	CcSEcCtD
Agomelatine—Hepatic failure—Docetaxel—ovarian cancer	0.00465	0.00516	CcSEcCtD
Agomelatine—Nasopharyngitis—Paclitaxel—ovarian cancer	0.00441	0.00489	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.00437	0.00484	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.00428	0.00474	CcSEcCtD
Agomelatine—Back pain—Vinorelbine—ovarian cancer	0.00427	0.00473	CcSEcCtD
Agomelatine—Influenza—Paclitaxel—ovarian cancer	0.00427	0.00473	CcSEcCtD
Agomelatine—Infection—Topotecan—ovarian cancer	0.00419	0.00464	CcSEcCtD
Agomelatine—Dyspepsia—Chlorambucil—ovarian cancer	0.00417	0.00462	CcSEcCtD
Agomelatine—Nervous system disorder—Topotecan—ovarian cancer	0.00413	0.00458	CcSEcCtD
Agomelatine—Migraine—Docetaxel—ovarian cancer	0.00412	0.00456	CcSEcCtD
Agomelatine—Infection—Melphalan—ovarian cancer	0.0041	0.00454	CcSEcCtD
Agomelatine—Skin disorder—Topotecan—ovarian cancer	0.00409	0.00454	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00409	0.00453	CcSEcCtD
Agomelatine—Fatigue—Chlorambucil—ovarian cancer	0.00408	0.00452	CcSEcCtD
Agomelatine—Hyperhidrosis—Topotecan—ovarian cancer	0.00408	0.00451	CcSEcCtD
Agomelatine—Angioedema—Vinorelbine—ovarian cancer	0.00404	0.00447	CcSEcCtD
Agomelatine—Skin disorder—Melphalan—ovarian cancer	0.00401	0.00444	CcSEcCtD
Agomelatine—Vertigo—Vinorelbine—ovarian cancer	0.00397	0.0044	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Epirubicin—ovarian cancer	0.00389	0.00431	CcSEcCtD
Agomelatine—Weight increased—Paclitaxel—ovarian cancer	0.00388	0.0043	CcSEcCtD
Agomelatine—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.00387	0.00429	CcSEcCtD
Agomelatine—Weight decreased—Paclitaxel—ovarian cancer	0.00386	0.00428	CcSEcCtD
Agomelatine—Abnormal dreams—Epirubicin—ovarian cancer	0.00384	0.00426	CcSEcCtD
Agomelatine—Infestation NOS—Paclitaxel—ovarian cancer	0.0038	0.00421	CcSEcCtD
Agomelatine—Infestation—Paclitaxel—ovarian cancer	0.0038	0.00421	CcSEcCtD
Agomelatine—Depression—Paclitaxel—ovarian cancer	0.00379	0.0042	CcSEcCtD
Agomelatine—Paraesthesia—Topotecan—ovarian cancer	0.00379	0.00419	CcSEcCtD
Agomelatine—Urticaria—Chlorambucil—ovarian cancer	0.00376	0.00417	CcSEcCtD
Agomelatine—Abdominal pain—Chlorambucil—ovarian cancer	0.00374	0.00415	CcSEcCtD
Agomelatine—Nasopharyngitis—Docetaxel—ovarian cancer	0.00374	0.00414	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.00374	0.00414	CcSEcCtD
Agomelatine—Dyspepsia—Topotecan—ovarian cancer	0.00371	0.00411	CcSEcCtD
Agomelatine—Paraesthesia—Melphalan—ovarian cancer	0.00371	0.00411	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00364	0.00403	CcSEcCtD
Agomelatine—Fatigue—Topotecan—ovarian cancer	0.00363	0.00403	CcSEcCtD
Agomelatine—Dyspepsia—Melphalan—ovarian cancer	0.00363	0.00403	CcSEcCtD
Agomelatine—Constipation—Topotecan—ovarian cancer	0.00361	0.00399	CcSEcCtD
Agomelatine—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.0036	0.00398	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Doxorubicin—ovarian cancer	0.0036	0.00398	CcSEcCtD
Agomelatine—Infection—Vinorelbine—ovarian cancer	0.00358	0.00397	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00356	0.00395	CcSEcCtD
Agomelatine—Fatigue—Melphalan—ovarian cancer	0.00356	0.00394	CcSEcCtD
Agomelatine—Abnormal dreams—Doxorubicin—ovarian cancer	0.00355	0.00394	CcSEcCtD
Agomelatine—Nervous system disorder—Vinorelbine—ovarian cancer	0.00354	0.00392	CcSEcCtD
Agomelatine—Skin disorder—Vinorelbine—ovarian cancer	0.0035	0.00388	CcSEcCtD
Agomelatine—Gastrointestinal pain—Topotecan—ovarian cancer	0.00345	0.00382	CcSEcCtD
Agomelatine—Asthenia—Chlorambucil—ovarian cancer	0.0034	0.00376	CcSEcCtD
Agomelatine—Connective tissue disorder—Paclitaxel—ovarian cancer	0.00336	0.00372	CcSEcCtD
Agomelatine—Pruritus—Chlorambucil—ovarian cancer	0.00335	0.00371	CcSEcCtD
Agomelatine—Urticaria—Topotecan—ovarian cancer	0.00335	0.00371	CcSEcCtD
Agomelatine—Abdominal pain—Topotecan—ovarian cancer	0.00333	0.00369	CcSEcCtD
Agomelatine—Weight increased—Docetaxel—ovarian cancer	0.00329	0.00365	CcSEcCtD
Agomelatine—Urticaria—Melphalan—ovarian cancer	0.00328	0.00363	CcSEcCtD
Agomelatine—Weight decreased—Docetaxel—ovarian cancer	0.00327	0.00362	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Epirubicin—ovarian cancer	0.00324	0.00359	CcSEcCtD
Agomelatine—Diarrhoea—Chlorambucil—ovarian cancer	0.00324	0.00359	CcSEcCtD
Agomelatine—Paraesthesia—Vinorelbine—ovarian cancer	0.00324	0.00359	CcSEcCtD
Agomelatine—Infestation NOS—Docetaxel—ovarian cancer	0.00322	0.00357	CcSEcCtD
Agomelatine—Infestation—Docetaxel—ovarian cancer	0.00322	0.00357	CcSEcCtD
Agomelatine—Eye disorder—Paclitaxel—ovarian cancer	0.00319	0.00353	CcSEcCtD
Agomelatine—Tinnitus—Paclitaxel—ovarian cancer	0.00318	0.00353	CcSEcCtD
Agomelatine—Jaundice—Docetaxel—ovarian cancer	0.00314	0.00348	CcSEcCtD
Agomelatine—Eczema—Epirubicin—ovarian cancer	0.00314	0.00348	CcSEcCtD
Agomelatine—Hepatic failure—Epirubicin—ovarian cancer	0.00314	0.00348	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00311	0.00345	CcSEcCtD
Agomelatine—Fatigue—Vinorelbine—ovarian cancer	0.00311	0.00344	CcSEcCtD
Agomelatine—Constipation—Vinorelbine—ovarian cancer	0.00308	0.00342	CcSEcCtD
Agomelatine—Hepatobiliary disease—Docetaxel—ovarian cancer	0.00305	0.00338	CcSEcCtD
Agomelatine—Asthenia—Topotecan—ovarian cancer	0.00302	0.00335	CcSEcCtD
Agomelatine—Vomiting—Chlorambucil—ovarian cancer	0.00301	0.00334	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Doxorubicin—ovarian cancer	0.003	0.00333	CcSEcCtD
Agomelatine—Mental disorder—Paclitaxel—ovarian cancer	0.00299	0.00331	CcSEcCtD
Agomelatine—Pruritus—Topotecan—ovarian cancer	0.00298	0.0033	CcSEcCtD
Agomelatine—Asthenia—Melphalan—ovarian cancer	0.00296	0.00328	CcSEcCtD
Agomelatine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00295	0.00327	CcSEcCtD
Agomelatine—Pruritus—Melphalan—ovarian cancer	0.00292	0.00324	CcSEcCtD
Agomelatine—Eczema—Doxorubicin—ovarian cancer	0.00291	0.00322	CcSEcCtD
Agomelatine—Hepatic failure—Doxorubicin—ovarian cancer	0.00291	0.00322	CcSEcCtD
Agomelatine—Hepatitis—Docetaxel—ovarian cancer	0.00289	0.00321	CcSEcCtD
Agomelatine—Diarrhoea—Topotecan—ovarian cancer	0.00288	0.0032	CcSEcCtD
Agomelatine—Back pain—Paclitaxel—ovarian cancer	0.00287	0.00318	CcSEcCtD
Agomelatine—Urticaria—Vinorelbine—ovarian cancer	0.00286	0.00317	CcSEcCtD
Agomelatine—Abdominal pain—Vinorelbine—ovarian cancer	0.00285	0.00316	CcSEcCtD
Agomelatine—Connective tissue disorder—Docetaxel—ovarian cancer	0.00284	0.00315	CcSEcCtD
Agomelatine—Diarrhoea—Melphalan—ovarian cancer	0.00282	0.00313	CcSEcCtD
Agomelatine—Nausea—Chlorambucil—ovarian cancer	0.00281	0.00312	CcSEcCtD
Agomelatine—Vision blurred—Paclitaxel—ovarian cancer	0.0028	0.0031	CcSEcCtD
Agomelatine—Dizziness—Topotecan—ovarian cancer	0.00279	0.00309	CcSEcCtD
Agomelatine—Tremor—Paclitaxel—ovarian cancer	0.00278	0.00308	CcSEcCtD
Agomelatine—Migraine—Epirubicin—ovarian cancer	0.00278	0.00308	CcSEcCtD
Agomelatine—Agitation—Paclitaxel—ovarian cancer	0.00273	0.00303	CcSEcCtD
Agomelatine—Face oedema—Epirubicin—ovarian cancer	0.00272	0.00302	CcSEcCtD
Agomelatine—Angioedema—Paclitaxel—ovarian cancer	0.00272	0.00301	CcSEcCtD
Agomelatine—Eye disorder—Docetaxel—ovarian cancer	0.0027	0.003	CcSEcCtD
Agomelatine—Vomiting—Topotecan—ovarian cancer	0.00268	0.00297	CcSEcCtD
Agomelatine—Vertigo—Paclitaxel—ovarian cancer	0.00267	0.00296	CcSEcCtD
Agomelatine—Headache—Topotecan—ovarian cancer	0.00264	0.00293	CcSEcCtD
Agomelatine—Vomiting—Melphalan—ovarian cancer	0.00262	0.00291	CcSEcCtD
Agomelatine—Asthenia—Vinorelbine—ovarian cancer	0.00259	0.00287	CcSEcCtD
Agomelatine—Migraine—Doxorubicin—ovarian cancer	0.00257	0.00285	CcSEcCtD
Agomelatine—Pruritus—Vinorelbine—ovarian cancer	0.00255	0.00283	CcSEcCtD
Agomelatine—Mental disorder—Docetaxel—ovarian cancer	0.00254	0.00281	CcSEcCtD
Agomelatine—Nasopharyngitis—Epirubicin—ovarian cancer	0.00252	0.0028	CcSEcCtD
Agomelatine—Anxiety—Paclitaxel—ovarian cancer	0.00252	0.00279	CcSEcCtD
Agomelatine—Face oedema—Doxorubicin—ovarian cancer	0.00252	0.00279	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00251	0.00278	CcSEcCtD
Agomelatine—Nausea—Topotecan—ovarian cancer	0.0025	0.00277	CcSEcCtD
Agomelatine—Dry mouth—Paclitaxel—ovarian cancer	0.00247	0.00274	CcSEcCtD
Agomelatine—Diarrhoea—Vinorelbine—ovarian cancer	0.00247	0.00273	CcSEcCtD
Agomelatine—Nausea—Melphalan—ovarian cancer	0.00245	0.00272	CcSEcCtD
Agomelatine—Influenza—Epirubicin—ovarian cancer	0.00244	0.0027	CcSEcCtD
Agomelatine—Back pain—Docetaxel—ovarian cancer	0.00244	0.0027	CcSEcCtD
Agomelatine—Infection—Paclitaxel—ovarian cancer	0.00241	0.00267	CcSEcCtD
Agomelatine—Indomethacin—ABCB1—ovarian cancer	0.0024	0.089	CrCbGaD
Agomelatine—Dizziness—Vinorelbine—ovarian cancer	0.00238	0.00264	CcSEcCtD
Agomelatine—Nervous system disorder—Paclitaxel—ovarian cancer	0.00238	0.00264	CcSEcCtD
Agomelatine—Skin disorder—Paclitaxel—ovarian cancer	0.00236	0.00261	CcSEcCtD
Agomelatine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00234	0.0026	CcSEcCtD
Agomelatine—Nasopharyngitis—Doxorubicin—ovarian cancer	0.00233	0.00259	CcSEcCtD
Agomelatine—Vomiting—Vinorelbine—ovarian cancer	0.00229	0.00254	CcSEcCtD
Agomelatine—Headache—Vinorelbine—ovarian cancer	0.00226	0.0025	CcSEcCtD
Agomelatine—Influenza—Doxorubicin—ovarian cancer	0.00226	0.0025	CcSEcCtD
Agomelatine—Weight increased—Epirubicin—ovarian cancer	0.00222	0.00246	CcSEcCtD
Agomelatine—Weight decreased—Epirubicin—ovarian cancer	0.00221	0.00244	CcSEcCtD
Agomelatine—Insomnia—Paclitaxel—ovarian cancer	0.00219	0.00243	CcSEcCtD
Agomelatine—Paraesthesia—Paclitaxel—ovarian cancer	0.00218	0.00241	CcSEcCtD
Agomelatine—Infestation—Epirubicin—ovarian cancer	0.00217	0.00241	CcSEcCtD
Agomelatine—Infestation NOS—Epirubicin—ovarian cancer	0.00217	0.00241	CcSEcCtD
Agomelatine—Somnolence—Paclitaxel—ovarian cancer	0.00216	0.00239	CcSEcCtD
Agomelatine—Nausea—Vinorelbine—ovarian cancer	0.00214	0.00237	CcSEcCtD
Agomelatine—Dyspepsia—Paclitaxel—ovarian cancer	0.00214	0.00237	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00213	0.00236	CcSEcCtD
Agomelatine—Jaundice—Epirubicin—ovarian cancer	0.00212	0.00235	CcSEcCtD
Agomelatine—Dry mouth—Docetaxel—ovarian cancer	0.0021	0.00232	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00209	0.00232	CcSEcCtD
Agomelatine—Fatigue—Paclitaxel—ovarian cancer	0.00209	0.00232	CcSEcCtD
Agomelatine—Constipation—Paclitaxel—ovarian cancer	0.00207	0.0023	CcSEcCtD
Agomelatine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.00206	0.00228	CcSEcCtD
Agomelatine—Weight increased—Doxorubicin—ovarian cancer	0.00205	0.00227	CcSEcCtD
Agomelatine—Infection—Docetaxel—ovarian cancer	0.00204	0.00226	CcSEcCtD
Agomelatine—Weight decreased—Doxorubicin—ovarian cancer	0.00204	0.00226	CcSEcCtD
Agomelatine—Nervous system disorder—Docetaxel—ovarian cancer	0.00202	0.00223	CcSEcCtD
Agomelatine—Infestation NOS—Doxorubicin—ovarian cancer	0.00201	0.00223	CcSEcCtD
Agomelatine—Infestation—Doxorubicin—ovarian cancer	0.00201	0.00223	CcSEcCtD
Agomelatine—Skin disorder—Docetaxel—ovarian cancer	0.002	0.00221	CcSEcCtD
Agomelatine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00198	0.0022	CcSEcCtD
Agomelatine—Jaundice—Doxorubicin—ovarian cancer	0.00196	0.00217	CcSEcCtD
Agomelatine—Hepatitis—Epirubicin—ovarian cancer	0.00195	0.00216	CcSEcCtD
Agomelatine—Urticaria—Paclitaxel—ovarian cancer	0.00193	0.00213	CcSEcCtD
Agomelatine—Connective tissue disorder—Epirubicin—ovarian cancer	0.00192	0.00212	CcSEcCtD
Agomelatine—Abdominal pain—Paclitaxel—ovarian cancer	0.00192	0.00212	CcSEcCtD
Agomelatine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.0019	0.00211	CcSEcCtD
Agomelatine—Insomnia—Docetaxel—ovarian cancer	0.00186	0.00206	CcSEcCtD
Agomelatine—Paraesthesia—Docetaxel—ovarian cancer	0.00185	0.00205	CcSEcCtD
Agomelatine—Somnolence—Docetaxel—ovarian cancer	0.00183	0.00202	CcSEcCtD
Agomelatine—Eye disorder—Epirubicin—ovarian cancer	0.00182	0.00202	CcSEcCtD
Agomelatine—Tinnitus—Epirubicin—ovarian cancer	0.00182	0.00202	CcSEcCtD
Agomelatine—Dyspepsia—Docetaxel—ovarian cancer	0.00181	0.002	CcSEcCtD
Agomelatine—Hepatitis—Doxorubicin—ovarian cancer	0.00181	0.002	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00178	0.00197	CcSEcCtD
Agomelatine—Connective tissue disorder—Doxorubicin—ovarian cancer	0.00177	0.00197	CcSEcCtD
Agomelatine—Fatigue—Docetaxel—ovarian cancer	0.00177	0.00196	CcSEcCtD
Agomelatine—Constipation—Docetaxel—ovarian cancer	0.00176	0.00195	CcSEcCtD
Agomelatine—Asthenia—Paclitaxel—ovarian cancer	0.00174	0.00193	CcSEcCtD
Agomelatine—Pruritus—Paclitaxel—ovarian cancer	0.00172	0.0019	CcSEcCtD
Agomelatine—Mental disorder—Epirubicin—ovarian cancer	0.00171	0.00189	CcSEcCtD
Agomelatine—Eye disorder—Doxorubicin—ovarian cancer	0.00169	0.00187	CcSEcCtD
Agomelatine—Tinnitus—Doxorubicin—ovarian cancer	0.00168	0.00187	CcSEcCtD
Agomelatine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00168	0.00186	CcSEcCtD
Agomelatine—Diarrhoea—Paclitaxel—ovarian cancer	0.00166	0.00184	CcSEcCtD
Agomelatine—Back pain—Epirubicin—ovarian cancer	0.00164	0.00182	CcSEcCtD
Agomelatine—Abdominal pain—Docetaxel—ovarian cancer	0.00163	0.0018	CcSEcCtD
Agomelatine—Dizziness—Paclitaxel—ovarian cancer	0.0016	0.00178	CcSEcCtD
Agomelatine—Vision blurred—Epirubicin—ovarian cancer	0.0016	0.00177	CcSEcCtD
Agomelatine—Mental disorder—Doxorubicin—ovarian cancer	0.00158	0.00175	CcSEcCtD
Agomelatine—Agitation—Epirubicin—ovarian cancer	0.00156	0.00173	CcSEcCtD
Agomelatine—Vomiting—Paclitaxel—ovarian cancer	0.00154	0.00171	CcSEcCtD
Agomelatine—Vertigo—Epirubicin—ovarian cancer	0.00153	0.00169	CcSEcCtD
Agomelatine—Back pain—Doxorubicin—ovarian cancer	0.00152	0.00168	CcSEcCtD
Agomelatine—Headache—Paclitaxel—ovarian cancer	0.00152	0.00168	CcSEcCtD
Agomelatine—Vision blurred—Doxorubicin—ovarian cancer	0.00148	0.00164	CcSEcCtD
Agomelatine—Asthenia—Docetaxel—ovarian cancer	0.00148	0.00163	CcSEcCtD
Agomelatine—Pruritus—Docetaxel—ovarian cancer	0.00145	0.00161	CcSEcCtD
Agomelatine—Agitation—Doxorubicin—ovarian cancer	0.00144	0.0016	CcSEcCtD
Agomelatine—Anxiety—Epirubicin—ovarian cancer	0.00144	0.0016	CcSEcCtD
Agomelatine—Nausea—Paclitaxel—ovarian cancer	0.00144	0.0016	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00144	0.00159	CcSEcCtD
Agomelatine—Dry mouth—Epirubicin—ovarian cancer	0.00141	0.00157	CcSEcCtD
Agomelatine—Vertigo—Doxorubicin—ovarian cancer	0.00141	0.00156	CcSEcCtD
Agomelatine—Diarrhoea—Docetaxel—ovarian cancer	0.00141	0.00156	CcSEcCtD
Agomelatine—Infection—Epirubicin—ovarian cancer	0.00138	0.00153	CcSEcCtD
Agomelatine—Nervous system disorder—Epirubicin—ovarian cancer	0.00136	0.00151	CcSEcCtD
Agomelatine—Dizziness—Docetaxel—ovarian cancer	0.00136	0.00151	CcSEcCtD
Agomelatine—Skin disorder—Epirubicin—ovarian cancer	0.00135	0.00149	CcSEcCtD
Agomelatine—Hyperhidrosis—Epirubicin—ovarian cancer	0.00134	0.00149	CcSEcCtD
Agomelatine—Anxiety—Doxorubicin—ovarian cancer	0.00133	0.00148	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.00133	0.00147	CcSEcCtD
Agomelatine—Dry mouth—Doxorubicin—ovarian cancer	0.00131	0.00145	CcSEcCtD
Agomelatine—Vomiting—Docetaxel—ovarian cancer	0.00131	0.00145	CcSEcCtD
Agomelatine—Headache—Docetaxel—ovarian cancer	0.00129	0.00143	CcSEcCtD
Agomelatine—Infection—Doxorubicin—ovarian cancer	0.00127	0.00141	CcSEcCtD
Agomelatine—Nervous system disorder—Doxorubicin—ovarian cancer	0.00126	0.00139	CcSEcCtD
Agomelatine—Insomnia—Epirubicin—ovarian cancer	0.00125	0.00139	CcSEcCtD
Agomelatine—Skin disorder—Doxorubicin—ovarian cancer	0.00125	0.00138	CcSEcCtD
Agomelatine—Paraesthesia—Epirubicin—ovarian cancer	0.00125	0.00138	CcSEcCtD
Agomelatine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.00124	0.00137	CcSEcCtD
Agomelatine—Somnolence—Epirubicin—ovarian cancer	0.00123	0.00137	CcSEcCtD
Agomelatine—Nausea—Docetaxel—ovarian cancer	0.00122	0.00135	CcSEcCtD
Agomelatine—Dyspepsia—Epirubicin—ovarian cancer	0.00122	0.00135	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.0012	0.00133	CcSEcCtD
Agomelatine—Fatigue—Epirubicin—ovarian cancer	0.0012	0.00132	CcSEcCtD
Agomelatine—Constipation—Epirubicin—ovarian cancer	0.00119	0.00131	CcSEcCtD
Agomelatine—Insomnia—Doxorubicin—ovarian cancer	0.00116	0.00129	CcSEcCtD
Agomelatine—Paraesthesia—Doxorubicin—ovarian cancer	0.00115	0.00128	CcSEcCtD
Agomelatine—Somnolence—Doxorubicin—ovarian cancer	0.00114	0.00126	CcSEcCtD
Agomelatine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.00113	0.00126	CcSEcCtD
Agomelatine—Dyspepsia—Doxorubicin—ovarian cancer	0.00113	0.00125	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00111	0.00123	CcSEcCtD
Agomelatine—Fatigue—Doxorubicin—ovarian cancer	0.00111	0.00123	CcSEcCtD
Agomelatine—Urticaria—Epirubicin—ovarian cancer	0.0011	0.00122	CcSEcCtD
Agomelatine—Constipation—Doxorubicin—ovarian cancer	0.0011	0.00122	CcSEcCtD
Agomelatine—Abdominal pain—Epirubicin—ovarian cancer	0.0011	0.00121	CcSEcCtD
Agomelatine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.00105	0.00116	CcSEcCtD
Agomelatine—Urticaria—Doxorubicin—ovarian cancer	0.00102	0.00113	CcSEcCtD
Agomelatine—Abdominal pain—Doxorubicin—ovarian cancer	0.00101	0.00112	CcSEcCtD
Agomelatine—Asthenia—Epirubicin—ovarian cancer	0.000995	0.0011	CcSEcCtD
Agomelatine—Pruritus—Epirubicin—ovarian cancer	0.000981	0.00109	CcSEcCtD
Agomelatine—Diarrhoea—Epirubicin—ovarian cancer	0.000949	0.00105	CcSEcCtD
Agomelatine—Asthenia—Doxorubicin—ovarian cancer	0.000921	0.00102	CcSEcCtD
Agomelatine—Dizziness—Epirubicin—ovarian cancer	0.000917	0.00102	CcSEcCtD
Agomelatine—Pruritus—Doxorubicin—ovarian cancer	0.000908	0.00101	CcSEcCtD
Agomelatine—Vomiting—Epirubicin—ovarian cancer	0.000882	0.000977	CcSEcCtD
Agomelatine—Diarrhoea—Doxorubicin—ovarian cancer	0.000878	0.000973	CcSEcCtD
Agomelatine—Headache—Epirubicin—ovarian cancer	0.000869	0.000962	CcSEcCtD
Agomelatine—Dizziness—Doxorubicin—ovarian cancer	0.000849	0.00094	CcSEcCtD
Agomelatine—Nausea—Epirubicin—ovarian cancer	0.000824	0.000913	CcSEcCtD
Agomelatine—Vomiting—Doxorubicin—ovarian cancer	0.000816	0.000904	CcSEcCtD
Agomelatine—Headache—Doxorubicin—ovarian cancer	0.000804	0.00089	CcSEcCtD
Agomelatine—Nausea—Doxorubicin—ovarian cancer	0.000762	0.000844	CcSEcCtD
Agomelatine—MTNR1B—Signaling by GPCR—KRAS—ovarian cancer	8.32e-05	0.00118	CbGpPWpGaD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	8.03e-05	0.00114	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HDAC6—ovarian cancer	8e-05	0.00114	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	7.93e-05	0.00113	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	7.93e-05	0.00113	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PPP2R1A—ovarian cancer	7.9e-05	0.00112	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	7.89e-05	0.00112	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NME2—ovarian cancer	7.89e-05	0.00112	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	7.83e-05	0.00111	CbGpPWpGaD
Agomelatine—HTR2C—G alpha (q) signalling events—PIK3CA—ovarian cancer	7.69e-05	0.00109	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—PIK3CA—ovarian cancer	7.65e-05	0.00109	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—PIK3CA—ovarian cancer	7.65e-05	0.00109	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—CXCL8—ovarian cancer	7.58e-05	0.00108	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	7.55e-05	0.00107	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—ERBB2—ovarian cancer	7.51e-05	0.00107	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—ERBB2—ovarian cancer	7.51e-05	0.00107	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	7.49e-05	0.00106	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MTOR—ovarian cancer	7.41e-05	0.00105	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MTOR—ovarian cancer	7.41e-05	0.00105	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PIK3CB—ovarian cancer	7.41e-05	0.00105	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PIK3CB—ovarian cancer	7.41e-05	0.00105	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CXCL8—ovarian cancer	7.12e-05	0.00101	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CXCL8—ovarian cancer	7.12e-05	0.00101	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—YAP1—ovarian cancer	7.08e-05	0.00101	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—HRAS—ovarian cancer	7.07e-05	0.00101	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—HRAS—ovarian cancer	7.07e-05	0.00101	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CDKN1B—ovarian cancer	6.95e-05	0.000988	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CDKN1B—ovarian cancer	6.95e-05	0.000988	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—XIAP—ovarian cancer	6.94e-05	0.000986	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	6.88e-05	0.000978	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—AKT1—ovarian cancer	6.88e-05	0.000977	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—AKT1—ovarian cancer	6.88e-05	0.000977	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CASP3—ovarian cancer	6.82e-05	0.000968	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CASP3—ovarian cancer	6.82e-05	0.000968	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IL2—ovarian cancer	6.8e-05	0.000967	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IL2—ovarian cancer	6.8e-05	0.000967	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—IL6—ovarian cancer	6.77e-05	0.000962	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—IL6—ovarian cancer	6.77e-05	0.000962	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SMARCA4—ovarian cancer	6.76e-05	0.000961	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	6.69e-05	0.000951	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CCND1—ovarian cancer	6.63e-05	0.000943	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CCND1—ovarian cancer	6.63e-05	0.000943	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EREG—ovarian cancer	6.6e-05	0.000938	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CTNNB1—ovarian cancer	6.57e-05	0.000933	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CTNNB1—ovarian cancer	6.57e-05	0.000933	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HDAC6—ovarian cancer	6.46e-05	0.000917	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MMP9—ovarian cancer	6.44e-05	0.000915	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MMP9—ovarian cancer	6.44e-05	0.000915	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PTEN—ovarian cancer	6.4e-05	0.00091	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PTEN—ovarian cancer	6.4e-05	0.00091	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	6.38e-05	0.000907	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PPP2R1A—ovarian cancer	6.37e-05	0.000905	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	6.37e-05	0.000905	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—AKT1—ovarian cancer	6.25e-05	0.000888	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—AKT1—ovarian cancer	6.25e-05	0.000888	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PGR—ovarian cancer	6.18e-05	0.000879	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—CXCL8—ovarian cancer	6.12e-05	0.000869	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	6.09e-05	0.000866	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYTB—ovarian cancer	5.95e-05	0.000845	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CG—ovarian cancer	5.82e-05	0.000827	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	5.81e-05	0.000826	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—VEGFA—ovarian cancer	5.78e-05	0.000822	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—VEGFA—ovarian cancer	5.78e-05	0.000822	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PARP1—ovarian cancer	5.75e-05	0.000817	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—STAT3—ovarian cancer	5.73e-05	0.000814	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—STAT3—ovarian cancer	5.73e-05	0.000814	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—YAP1—ovarian cancer	5.71e-05	0.000812	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NRAS—ovarian cancer	5.71e-05	0.000812	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NRAS—ovarian cancer	5.71e-05	0.000812	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—XIAP—ovarian cancer	5.6e-05	0.000795	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL6ST—ovarian cancer	5.5e-05	0.000782	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MAPK3—ovarian cancer	5.47e-05	0.000777	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MAPK3—ovarian cancer	5.47e-05	0.000777	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SMARCA4—ovarian cancer	5.46e-05	0.000775	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.46e-05	0.000775	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EREG—ovarian cancer	5.32e-05	0.000757	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MYC—ovarian cancer	5.32e-05	0.000756	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MYC—ovarian cancer	5.32e-05	0.000756	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CG—ovarian cancer	5.28e-05	0.000751	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MAPK1—ovarian cancer	5.21e-05	0.00074	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MAPK1—ovarian cancer	5.21e-05	0.00074	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—EGFR—ovarian cancer	5.2e-05	0.00074	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—EGFR—ovarian cancer	5.2e-05	0.00074	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—BRIP1—ovarian cancer	5.2e-05	0.000739	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PPP1CC—ovarian cancer	5.2e-05	0.000739	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CD—ovarian cancer	5.12e-05	0.000727	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYTB—ovarian cancer	5.08e-05	0.000722	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PGR—ovarian cancer	4.99e-05	0.000709	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.97e-05	0.000706	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—KRAS—ovarian cancer	4.92e-05	0.000699	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—KRAS—ovarian cancer	4.92e-05	0.000699	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CG—ovarian cancer	4.69e-05	0.000667	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PPP2R1A—ovarian cancer	4.66e-05	0.000663	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CD—ovarian cancer	4.65e-05	0.00066	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PARP1—ovarian cancer	4.64e-05	0.000659	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PIK3CA—ovarian cancer	4.52e-05	0.000642	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PIK3CA—ovarian cancer	4.52e-05	0.000642	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CB—ovarian cancer	4.46e-05	0.000634	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PPP1CC—ovarian cancer	4.44e-05	0.000631	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—BRIP1—ovarian cancer	4.44e-05	0.000631	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL6ST—ovarian cancer	4.44e-05	0.00063	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TP53—ovarian cancer	4.37e-05	0.000621	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TP53—ovarian cancer	4.37e-05	0.000621	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—CXCL8—ovarian cancer	4.28e-05	0.000609	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CG—ovarian cancer	4.26e-05	0.000606	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—HRAS—ovarian cancer	4.18e-05	0.000594	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—HRAS—ovarian cancer	4.18e-05	0.000594	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CD—ovarian cancer	4.13e-05	0.000586	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—IL2—ovarian cancer	4.1e-05	0.000582	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CB—ovarian cancer	4.05e-05	0.000575	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IL6—ovarian cancer	4e-05	0.000568	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IL6—ovarian cancer	4e-05	0.000568	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—CXCL8—ovarian cancer	3.89e-05	0.000553	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.79e-05	0.000538	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PPP2R1A—ovarian cancer	3.76e-05	0.000535	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CD—ovarian cancer	3.75e-05	0.000533	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL2—ovarian cancer	3.72e-05	0.000528	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TERT—ovarian cancer	3.71e-05	0.000526	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—AKT1—ovarian cancer	3.69e-05	0.000524	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—AKT1—ovarian cancer	3.69e-05	0.000524	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CB—ovarian cancer	3.6e-05	0.000511	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—YAP1—ovarian cancer	3.49e-05	0.000496	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—CXCL8—ovarian cancer	3.46e-05	0.000491	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.45e-05	0.00049	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CAV1—ovarian cancer	3.43e-05	0.000487	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—IL2—ovarian cancer	3.3e-05	0.000469	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ESR1—ovarian cancer	3.3e-05	0.000469	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CB—ovarian cancer	3.27e-05	0.000464	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL6ST—ovarian cancer	3.25e-05	0.000462	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.24e-05	0.00046	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CXCL8—ovarian cancer	3.14e-05	0.000446	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—APC—ovarian cancer	3.12e-05	0.000444	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CG—ovarian cancer	3.12e-05	0.000444	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—NRAS—ovarian cancer	3.12e-05	0.000444	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.03e-05	0.000431	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL2—ovarian cancer	3e-05	0.000426	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—MAPK3—ovarian cancer	2.99e-05	0.000425	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TERT—ovarian cancer	2.99e-05	0.000425	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—YAP1—ovarian cancer	2.98e-05	0.000423	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.95e-05	0.000419	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—MAPK1—ovarian cancer	2.84e-05	0.000404	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—EGFR—ovarian cancer	2.84e-05	0.000404	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—FASN—ovarian cancer	2.84e-05	0.000404	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC5A5—ovarian cancer	2.8e-05	0.000397	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CAV1—ovarian cancer	2.76e-05	0.000393	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CD—ovarian cancer	2.74e-05	0.00039	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CA—ovarian cancer	2.72e-05	0.000386	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC2A1—ovarian cancer	2.7e-05	0.000384	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—KRAS—ovarian cancer	2.69e-05	0.000382	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ESR1—ovarian cancer	2.66e-05	0.000379	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.64e-05	0.000376	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL6ST—ovarian cancer	2.62e-05	0.000372	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.59e-05	0.000368	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP1B1—ovarian cancer	2.59e-05	0.000368	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—APC—ovarian cancer	2.52e-05	0.000358	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CG—ovarian cancer	2.52e-05	0.000358	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—NRAS—ovarian cancer	2.52e-05	0.000358	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CA—ovarian cancer	2.47e-05	0.000351	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—FASN—ovarian cancer	2.43e-05	0.000345	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ERBB2—ovarian cancer	2.42e-05	0.000344	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—MAPK3—ovarian cancer	2.41e-05	0.000343	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CB—ovarian cancer	2.39e-05	0.00034	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MTOR—ovarian cancer	2.39e-05	0.00034	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC5A5—ovarian cancer	2.39e-05	0.00034	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC2A1—ovarian cancer	2.31e-05	0.000328	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CXCL8—ovarian cancer	2.3e-05	0.000327	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	2.3e-05	0.000326	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—MAPK1—ovarian cancer	2.29e-05	0.000326	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—EGFR—ovarian cancer	2.29e-05	0.000326	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.29e-05	0.000325	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—HRAS—ovarian cancer	2.28e-05	0.000325	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.26e-05	0.000321	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDKN1B—ovarian cancer	2.24e-05	0.000319	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—AKT1—ovarian cancer	2.22e-05	0.000316	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CD—ovarian cancer	2.21e-05	0.000315	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP1B1—ovarian cancer	2.21e-05	0.000314	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CASP3—ovarian cancer	2.2e-05	0.000313	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL2—ovarian cancer	2.2e-05	0.000312	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CA—ovarian cancer	2.19e-05	0.000312	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL6—ovarian cancer	2.19e-05	0.000311	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—KRAS—ovarian cancer	2.17e-05	0.000308	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCND1—ovarian cancer	2.14e-05	0.000304	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ABCB1—ovarian cancer	2.13e-05	0.000303	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CTNNB1—ovarian cancer	2.12e-05	0.000301	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TYMS—ovarian cancer	2.09e-05	0.000298	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MMP9—ovarian cancer	2.08e-05	0.000295	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTEN—ovarian cancer	2.07e-05	0.000294	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—AKT1—ovarian cancer	2.02e-05	0.000287	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CA—ovarian cancer	1.99e-05	0.000283	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.96e-05	0.000279	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ERBB2—ovarian cancer	1.96e-05	0.000278	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.95e-05	0.000278	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CB—ovarian cancer	1.93e-05	0.000274	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MTOR—ovarian cancer	1.93e-05	0.000274	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—VEGFA—ovarian cancer	1.87e-05	0.000265	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CXCL8—ovarian cancer	1.85e-05	0.000264	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—STAT3—ovarian cancer	1.85e-05	0.000263	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NRAS—ovarian cancer	1.84e-05	0.000262	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—HRAS—ovarian cancer	1.84e-05	0.000262	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.82e-05	0.000259	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN1B—ovarian cancer	1.81e-05	0.000257	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—AKT1—ovarian cancer	1.79e-05	0.000255	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TYMS—ovarian cancer	1.79e-05	0.000254	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CASP3—ovarian cancer	1.77e-05	0.000252	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL2—ovarian cancer	1.77e-05	0.000252	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK3—ovarian cancer	1.77e-05	0.000251	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL6—ovarian cancer	1.76e-05	0.000251	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCND1—ovarian cancer	1.73e-05	0.000245	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MYC—ovarian cancer	1.72e-05	0.000244	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CTNNB1—ovarian cancer	1.71e-05	0.000243	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CAV1—ovarian cancer	1.69e-05	0.00024	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK1—ovarian cancer	1.68e-05	0.000239	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EGFR—ovarian cancer	1.68e-05	0.000239	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MMP9—ovarian cancer	1.68e-05	0.000238	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTEN—ovarian cancer	1.67e-05	0.000237	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	1.63e-05	0.000231	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.61e-05	0.000229	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KRAS—ovarian cancer	1.59e-05	0.000226	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.54e-05	0.000218	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	1.51e-05	0.000214	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—STAT3—ovarian cancer	1.49e-05	0.000212	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NRAS—ovarian cancer	1.49e-05	0.000211	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	1.46e-05	0.000207	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CAV1—ovarian cancer	1.44e-05	0.000205	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	1.42e-05	0.000202	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—ovarian cancer	1.41e-05	0.0002	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MYC—ovarian cancer	1.39e-05	0.000197	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.38e-05	0.000196	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.36e-05	0.000193	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.36e-05	0.000193	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.35e-05	0.000192	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HRAS—ovarian cancer	1.35e-05	0.000192	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.31e-05	0.000187	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL6—ovarian cancer	1.29e-05	0.000183	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.28e-05	0.000182	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKT1—ovarian cancer	1.19e-05	0.000169	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.18e-05	0.000167	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	1.18e-05	0.000167	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.15e-05	0.000164	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—ovarian cancer	1.14e-05	0.000162	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	1.09e-05	0.000155	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL6—ovarian cancer	1.04e-05	0.000148	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTEN—ovarian cancer	1.02e-05	0.000145	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.01e-05	0.000143	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	9.61e-06	0.000137	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTEN—ovarian cancer	8.7e-06	0.000124	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CA—ovarian cancer	7.18e-06	0.000102	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	6.14e-06	8.72e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKT1—ovarian cancer	5.87e-06	8.33e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKT1—ovarian cancer	5.01e-06	7.12e-05	CbGpPWpGaD
